|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL.
|
29783918 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The APRIL codon 67 was significantly associated with SLE risk under the dominant model adjusted by ethnicity (odds ratio, 95% confidence interval and P-values were 1.45 and 1.02-2.06 and 0.036, respectively).
|
17569747 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.
|
27390168 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A single-nucleotide polymorphism (SNP) for rs11552708 of APRIL gene was analyzed by real-time PCR in 60 SLE Iranian children and 64 healthy controls.
|
27878683 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results have identified and confirmed APRIL as a new target involved in B-cell activation, in the maintenance of plasma cell survival and subsequent increased autoantibody production that sustains lupus development in mice.
|
28267197 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We previously reported the association of APRIL haplotypes formed by two nonsynonymous polymorphisms, Gly67Arg and Asn96Ser, with systemic lupus erythematosus.
|
21984075 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
|
26424128 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.
|
15308519 |
2004 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
|
30467093 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include the BAFF/APRIL dual inhibitor, atacicept, and the BAFF inhibitor, belimumab, which is approved as an add-on therapy for patients with active SLE.
|
28215100 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protective effect of APRIL c.199A/A homozygotes in SLE was replicated (odds ratio 0.50, 95% confidence interval 0.30-0.83, P = 0.0073; pooled P = 0.0001, Pcorr = 0.007).
|
17307753 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
BLyS and APRIL are cytokines from the tumor necrosis factor family which play an important role in systemic lupus erythematosus (SLE).
|
23171638 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus.
|
12730512 |
2003 |
|
Rheumatoid Arthritis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In addition, BAFF and APRIL are involved in the pathogenesis of a number of human autoimmune diseases, with elevated levels of these cytokines detected in the sera of patients with systemic lupus erythematosus (SLE), IgA nephropathy, Sjögren's syndrome, and rheumatoid arthritis.
|
28215100 |
2017 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
Association of APRIL and TWEAK with rheumatoid arthritis (RA) was examined in parallel.
|
17307753 |
2007 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
APRIL stimulated RA FLS, but not OA FLS, to produce IL-6, TNFalpha, IL-1beta, and APRIL itself.
|
17968879 |
2007 |
|
Rheumatoid Arthritis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
RASF, rheumatoid arthritis dermal fibroblasts (RADF) and osteoarthritis synovial fibroblasts (OASF) were analysed for the expression of B cell survival/proliferating factors BAFF and APRIL in resting conditions and upon stimulation with TLR2/TLR3/TLR4 ligands.
|
21798884 |
2011 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
The role of BAFF and APRIL in rheumatoid arthritis.
|
30941763 |
2019 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
BLyS and APRIL in rheumatoid arthritis.
|
16239971 |
2005 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
APRIL also promoted B10 cells in RA patients.
|
27372914 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
|
15488762 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
The CXCR5/CXCL13 pair by means of activation of APRIL (A proliferation-inducing ligand) induced resistance to apoptosis in T-ALL CD8(+)CD34(+) T cells in livin-dependent manner.
|
15580304 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features.
|
19395025 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
These findings indicate that APRIL has an important role in CLL and that the APRIL-TACI interaction might be a selective novel therapeutic target for human CLL.
|
24100449 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We further analysed the prognostic value of BAFF and APRIL receptors expression in patients with CLL.
|
24245956 |
2014 |